Latest Articles
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer - Medscape
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer Medscape
Published: June 22, 2026, 1 p.m.
Trastuzumab Pamirtecan Provides Meaningful Survival Benefit in Pretreated HER2-Expressing Endometrial Cancer - OncLive
Trastuzumab Pamirtecan Provides Meaningful Survival Benefit in Pretreated HER2-Expressing Endometrial Cancer OncLive
Published: June 17, 2026, 9:31 p.m.
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer - Medscape Reference
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer Medscape Reference
Published: June 17, 2026, 2:51 p.m.
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post
Published: June 3, 2026, 2:49 p.m.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer Oncodaily
Published: June 3, 2026, 3:15 a.m.
Pancreatic cancer breakthrough: New daily pill nearly doubles survival time in advanced patients - TheHealthSite
Pancreatic cancer breakthrough: New daily pill nearly doubles survival time in advanced patients TheHealthSite
Published: June 2, 2026, 10:11 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN
Published: June 2, 2026, 12:41 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress
Published: June 1, 2026, 8 p.m.
'White Days' play probes pain, silence and survival in women's reproductive health - standardmedia.co.ke
'White Days' play probes pain, silence and survival in women's reproductive health standardmedia.co.ke
Published: May 31, 2026, 12:58 p.m.
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients - News-Medical
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients News-Medical
Published: May 30, 2026, 2:16 a.m.
Link copied to clipboard!